Interferon gamma-1b
- Generic Name
- Interferon gamma-1b
- Brand Names
- Actimmune
- Drug Type
- Biotech
- CAS Number
- 98059-61-1
- Unique Ingredient Identifier
- 21K6M2I7AG
- Background
Human Interferon gamma-1b (140 residues), produced from E. coli. Production of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein. Purification of the product is achieved by conventional column chromatography.
The sequence displayed is a cDNA sequence which codes for human interferon gamma, as described by Gray et. al. and not specifically interferon gamma 1b.
- Indication
Interferon gamma-1b is used for the treatment of Chronic granulomatous disease and Osteopetrosis.
- Associated Conditions
- Chronic Granulomatous Disease (CGD), Severe, malignant Osteopetrosis
Amgen Reports Strong Global Demand in Q1 2025, Bolstering Long-Term Growth Outlook
• Amgen announced positive first quarter 2025 financial results, citing strong global demand across its product portfolio and successful new product launches.
• Chairman and CEO Bob Bradway expressed confidence in Amgen's long-term growth prospects, supported by recent successful Phase 3 clinical trial results for several products.
• The biotechnology company, which employs over 28,000 people globally, continues to focus on its mission of harnessing biology and technology to combat serious diseases.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath